Medicines and Healthcare products Regulatory Agency

gov.uk Imported from official source

UK medicines and medical devices regulator; recalls and safety alerts.

Publications 148

  1. Continuous renal replacement therapy (CRRT): Consider delayed administration of concurrent echinocandins, such as caspofungin, to reduce the risk of adsorption onto new polyacrylonitrile (PAN)-based filter membranes DSI/2026/014

    Continuous renal replacement therapy (CRRT) is used for managing severe acute kidney injury and fluid overload. Published evidence has shown that caspofungin can bind to polyacrylonitrile (PAN)-bas...

    Alert Safety
  2. Class 2 Medicines Recall: Norgine Pharmaceuticals Limited, Pedmarqsi 80 mg/mL solution for infusion, EL(26)A/42

    Norgine Pharmaceuticals Limited is recalling the batches listed in the table due to risk of particulate matter being present in the product identified during routine stability investigations.

    Alert Safety
  3. Nova Biomedical StatStrip ketone test strips: risk of disruption to blood ketone testing due to quality-control failures and supply interruption DSI/2026/013

    Nova Biomedical has identified quality issues affecting specified lots of StatStrip ketone test strips. The affected lots have been associated with quality-control (QC) failures and Nova Biomedical...

    Alert Safety
  4. Field Safety Notices: 28 September 2026 to 2 October 2026

    List of Field Safety Notices: 21 to 25 September 2026

    Alert Safety
  5. Research: Role of the Digital Mental Health Technology (DMHT) Working Group

    Find out how the Digital Mental Health Technology Working Group supported MHRA and NICE work on regulation, evaluation and AI priorities for DMHTs.

    Alert AI
  6. Research: Patient reported outcomes (PROs) resources for digital mental health technologies (DMHTs)

    Resources to help developers use patient-reported outcomes in digital mental health technologies for evidence generation, monitoring and user safety.

    Alert AI
  7. MHRA Chair Professor Anthony Harnden: Bringing our strategy to life – listening, learning, and looking ahead

    In the final instalment of our strategy blog series, MHRA Chair Professor Anthony Harnden reflects on the insights shared throughout the series and how innovation and collaboration across the UK ar...

    Alert Safety
  8. Guidance: MHRA Real-World Evidence: knowledge and guidance

    Supporting guidance, publications and resources on the use of real-world data (RWD) and real-world evidence (RWE) in regulatory decision-making for medicines and medical devices in the UK.

    Alert Safety
  9. Guidance: Pneumococcal Vaccine Factsheet – Information for Patients, Parents and Carers 

    Patient factsheet providing information on pneumococcal disease and pneumococcal vaccination.

    Alert Safety
  10. MHRA approves catumaxomab to treat cancer-related fluid build-up in the abdomen 

    As with all licensed medicines, the MHRA will keep the safety and effectiveness of catumaxomab under close review.

    Alert Safety
  11. Government backs recommendations of NHS doctors-led AI Commission

    Ministers back independent Commission's blueprint in full, while the MHRA's AI Airlock opens its next phase,

    Alert AI
  12. Guidance: What the National Commission’s recommendations mean for you

    How new recommendations could make healthcare AI safer, clearer and fairer for patients, professionals, providers and developers across the UK.

    Alert AI
  13. Guidance: AI Airlock Phase 3 application

    The call for applications for phase 3 of the AI Airlock is now open.

    Alert AI
  14. Policy paper: Government Response to the National Commission's Recommendations on the Regulation of AI in Healthcare.

    The government's response published on the 6 October 2026 to provide clarity to stakeholders on how the government intends to take forward the recommendations made by the independent National Commi...

    Alert AI
  15. Class 3 Medicines Recall: Norgine Limited, MOVICOL Plain 13.7g powder for oral solution, EL(26)A/41

    Norgine Limited is recalling specific batches of product as a precautionary measure due to some units containing the incorrect amounts of active ingredients.

    Alert Safety
  16. Electronic Application Forms (eAF) for UK medicines licensing applications

    Current eAF forms are available for applicants to download and use. Existing submission routes, validation requirements and assessment processes remain unchanged.

    Alert Safety
  17. Decision: Advertising investigations: September 2026

    Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines.

    Alert Safety
  18. MHRA joins global regulators in call to advance alternatives to animal testing

    International statement co-developed by UK medicines regulator

    Alert Safety
  19. Class 4 Medicines Defect Notification: Neuraxpharm UK Limited, Levetiracetam Neuraxpharm granules for oral solution in sachet, EL(26)A/40

    Neuraxpharm UK Limited have informed the MHRA that a review of the approved Patient Information Leaflet (PIL) has identified discrepancies between the current Neuraxpharm product safety information...

    Alert Safety
  20. DIA and MHRA announce speaker line-up for inaugural global summit

    International leaders will gather to address some of the most significant opportunities and challenges facing healthcare today at the DIA-MHRA Global Summit.

    Alert Safety
  21. Field Safety Notices: 21 to 25 September 2026

    List of Field Safety Notices from 21 to 25 September 2026.

    Alert Safety
  22. MHRA Safety Roundup: September 2026

    Summary of the latest safety advice for medicines and medical device users

    Alert Safety
  23. Professor Dame Anna Dominiczak, Professor Alison Strath, and Fiona Cohrane: Catalysing the medicines ecosystem in Scotland

    Scotland’s growing commercial research infrastructure and strong NHS, academic and industry partnerships are helping widen access to clinical trials, accelerate adoption and strengthen the UK life ...

    Alert Safety
  24. Five new commissioners appointed to the Commission on Human Medicines (CHM)

    The CHM provides independent expert advice to ministers on the safety, quality and efficacy of medicines.

    Alert Safety
  25. MHRA welcomes sentencing after fraud convictions over falsely certified medical devices

    Following convictions related to falsely certified medical devices, the MHRA has welcomed the sentencing in a long-running enforcement investigation.

    Alert Safety
  26. MHRA approves lurbinectedin for adults with extensive-stage small cell lung cancer   

    As with all licensed medicines, the MHRA will keep the safety and effectiveness of lurbinectedin under close review.

    Alert Safety
  27. Class 4 Medicines Defect Notification: B. Braun Melsungen AG, Meropenem 1000 mg powder and solvent for solution for infusion, EL(26)A/39

    B. Braun Melsungen AG has notified the MHRA that errors have been identified in the Patient Information Leaflet (PIL) included in some batches of Meropenem 1000 mg powder and solvent for solution f...

    Alert Safety
  28. Field Safety Notices: 14 to 18 September 2026

    List of Field Safety Notices from 14 to 18 September 2026.

    Alert Safety
  29. Beyond ADMET: AI for medicines safety - survey

    The MHRA and the Regulatory Innovation Office (RIO) invite organisations to share their views on the use of artificial intelligence (AI) in medicines development.

    Alert AI Safety
  30. Funding opportunity launched to strengthen UK regulatory science and support healthcare innovation  

    Four new centres of excellence will bring together expertise across academia, industry, healthcare and regulation to keep pace with advances in healthcare and life sciences

    Alert Safety
  31. Radiofrequency (RF) Safety Considerations for Wireless Cardiotocography (CTG) Monitoring Systems (DSI/2026/012)

    The MHRA has conducted a review into the use of wireless cardiotocography (CTG) systems that use radiofrequency (RF) telemetry channels. Signal crossover, erroneous CTG traces and signal dropouts h...

    Alert Safety
  32. Class 4 Medicines Defect Notification: Martindale Pharmaceuticals Ltd, Clobazam Martindale Pharma 5 mg/5 mL and 10 mg/5 mL Oral Suspension 150ml, EL(26)A/38

    Martindale Pharmaceuticals has informed the MHRA of an error with the linear barcode of some batches of Clobazam 5mg/5mL and 10mg/5mL Oral Suspension 150mL.

    Alert Safety
  33. MHRA sets out steps to prevent avoidable harm from patient hoists

    A National Patient Safety Alert has been issued setting out practical steps to reduce the risk of harm when using patient hoists through improved checks and maintenance.

    Alert Safety
  34. Guidance: National Patient Safety Alert Supporting Information. Patient hoists and slings: incidents and case examples.

    Supporting information to accompany the National Patient Safety Alert on patient hoists and slings NatPSA/2026/005/MHRA.

    Alert Safety
  35. National Patient Safety Alert: Patient hoists and slings (all types): risk of death and serious harm from falls (NatPSA/2026/005/MHRA)

    Fatal and serious harm continues to occur when patients fall from hoists or slings during transfers and repositioning. A review of recent incidents with a fatal outcome and wider surveillance data ...

    Alert Safety
  36. Beyond ADMET: AI for medicines safety stakeholder survey

    The MHRA and the Regulatory Innovation Office (RIO) invite organisations to share their views on the use of artificial intelligence (AI) in medicines development.

    Alert AI Safety Source page stopped responding
  37. MHRA and Malaysia strengthen partnership on healthcare innovation and research

    The MHRA has reaffirmed its commitment to strengthening regulatory collaboration with Malaysia following high-level discussions in Kuala Lumpur.

    Alert Safety
  38. Field Safety Notices: 7 September to 11 September 2026

    List of Field Safety Notices from 7 September to 11 September 2026.

    Alert Safety
  39. Independent Commission led by NHS doctors sets out blueprint to accelerate safe AI adoption in healthcare

    New recommendations based on extensive public engagement set out how the NHS could give patients faster access to AI advances with proportionate safeguards to protect patient safety and maintain hi...

    Alert AI Safety
  40. Research: National Commission into the Regulation of AI in Healthcare: Recommendations for a future regulatory framework

    Recommendations from the National Commission into the Regulation of AI in Healthcare, which was established to advise government on a future regulatory framework for AI in healthcare.

    Alert AI
  41. Field Safety Notices: 31 August to 4 September 2026

    List of Field Safety Notices from 31 August to 4 September 2026.

    Alert Safety
  42. Decision: Advertising investigations: August 2026

    Decisions made by MHRA on adverts reported to have breached the legislation on advertising medicines.

    Alert Safety
  43. Field Safety Notices: 24 to 28 August 2026

    List of Field Safety Notices from 24 to 28 August 2026.

    Alert Safety
  44. MHRA and Manchester NHS partner on health innovation sandbox

    New partnership to create health innovation sandbox that will test promising new technologies and build evidence to accelerate the safe adoption of technologies, including AI, in the NHS.

    Alert AI Safety
  45. Filters should be used during the administration of Parenteral Nutrition for patients in all care settings

    Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcome.

    Alert Safety
  46. Filters should be used during the administration of Parenteral Nutrition for patients in all care settings DSI/2026/011

    Administration of parenteral nutrition without a filter has been associated with a number of adverse incidents including an embolism which resulted in a fatal outcome.

    Alert Safety
  47. MHRA consultation on statutory fees (2026)

    Proposals for ongoing cost-recovery and to fund higher value services.

    Alert Safety
  48. Guidance: 14-day assessment stepwise implementation programme for Phase 1 clinical trials

    The stepwise implementation programme aims to deliver the first wave 1 regulatory assessment in 14 calendar days for qualifying applications by the end of 2026.

    Alert Safety
  49. Corporate report: MHRA quarterly Results and Forecast: 2026 to 2027

    Quarterly reports to provide performance information and projections across 2026/2027.

    Alert Safety

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.